Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities
暂无分享,去创建一个
D. Collyar | L. Chow | M. Butler | E. Rubin | P. Forde | C. Baik | J. Mehnert | E. L. Dixon | Erica L. Dixon
[1] L. Rubinstein,et al. The Challenge for Development of Valuable Immuno-oncology Biomarkers , 2017, Clinical Cancer Research.
[2] T. Dilling,et al. Tolerability and Safety of Thoracic Radiation and Immune Checkpoint Inhibitors Among Patients with Lung Cancer. , 2017, International journal of radiation oncology, biology, physics.
[3] C. Zahnow,et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. , 2017, Cancer discovery.
[4] G. Mason,et al. Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. , 2017, Journal of neurosurgery. Pediatrics.
[5] Carlos Barrios,et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.
[6] M. Harrison,et al. Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer , 2016, Clinical Cancer Research.
[7] J. Elassaiss-Schaap,et al. Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose‐Range Selection of the Anti–PD‐1 Antibody Pembrolizumab , 2016, CPT: pharmacometrics & systems pharmacology.
[8] Charles Ferté,et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.
[9] D. Gerber,et al. Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options. , 2016, JAMA oncology.
[10] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[11] Jinzhong Yang,et al. Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies , 2016, Front. Oncol..
[12] R. Sullivan,et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] Lajos Pusztai,et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Yu Shyr,et al. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade , 2016, Cancer Immunology Research.
[15] R. Berger,et al. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Kefford,et al. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma , 2016, Oncoimmunology.
[17] T. Graeber,et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.
[18] A. Vortmeyer,et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[19] J. Lunceford,et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.
[20] D. Jäger,et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.
[21] Jedd D. Wolchok,et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. , 2016 .
[22] S. Gettinger,et al. Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets). , 2016 .
[23] P. Sharma,et al. NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA). , 2016 .
[24] S. Khozin,et al. Characterization of patients treated with a programmed cell death protein 1 inhibitor (anti-PD-1) past RECIST progression from a metastatic non-small cell lung cancer (mNSCLC) trial. , 2016 .
[25] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[26] S. Moschos,et al. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. , 2016, Cancer treatment reviews.
[27] P. Keegan,et al. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1 , 2016, The oncologist.
[28] P. Medina,et al. PD‐1 Pathway Inhibitors: Immuno‐Oncology Agents for Restoring Antitumor Immune Responses , 2016, Pharmacotherapy.
[29] K. Steele,et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. , 2016, The Lancet. Oncology.
[30] J. Soria,et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.
[31] J. Soria,et al. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[33] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[34] R. Ahmed,et al. Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. , 2015, Neuro-oncology.
[35] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[36] Y. Yamada,et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. , 2015, International journal of radiation oncology, biology, physics.
[37] T. Yau,et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[39] Lon Smith,et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.
[40] S. Lewin,et al. Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. , 2015, AIDS.
[41] H. Ishwaran,et al. Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.
[42] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[43] E. Lipson,et al. Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series , 2014, Journal of Immunotherapy for Cancer.
[44] J. Wolchok,et al. Immune modulation for cancer therapy , 2014, British Journal of Cancer.
[45] B. Fox,et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. , 2013, Cancer research.
[46] R. Sékaly,et al. PD-1 coinhibitory signals: the link between pathogenesis and protection. , 2013, Seminars in immunology.
[47] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[48] H. Scher,et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[50] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[51] Jedd D. Wolchok,et al. Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.
[52] M. Sznol,et al. Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[54] Jorge A. Almenara,et al. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions , 2008, Molecular Cancer Therapeutics.
[55] R. Berger,et al. Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies , 2008, Clinical Cancer Research.
[56] B. Comin-Anduix,et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] R. Hansen,et al. Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.
[58] S. Gettinger,et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. , 2017, The Lancet. Oncology.
[59] A. Tafreshi,et al. PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024 , 2017 .
[60] Ipilimumab for Patients with Relapse after Allogeneic Transplantation. , 2016, The New England journal of medicine.
[61] S. Siva,et al. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. , 2015, Cancer letters.